MyoKardia (MYOK) PT Raised to $84 at Wedbush

Go back to MyoKardia (MYOK) PT Raised to $84 at Wedbush

MyoKardia (MYOK) Re-acquires Global Rights to Mavacamten and MYK-491 Programs from Sanofi (SNY)

January 2, 2019 8:13 AM EST

MyoKardia, Inc. (NASDAQ: MYOK) today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi (NYSE: SNY). The collaboration will not be extended beyond the initial research term, which ended on December 31, 2018, and will conclude in its entirety effective April 1, 2019. As a result, MyoKardia now has global rights to all programs in its portfolio, including lead clinical-stage candidates, mavacamten and MYK-491.

We are grateful for Sanofis support over the past four years in what was a highly productive... More